Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996410 | 0.96 | LMNA (0.34) | LMNASMN1; SMN2TDP1PSEN1PSEN2 | |
| SCHEMBL6999953 | 0.91 | TDP1 (0.33) | LMNASMN1; SMN2TDP1MDM2KMT2A | |
| SCHEMBL6995459 | 0.81 | POLB (0.33) | MAPT | |
| SCHEMBL6999384 | 0.81 | GRIA2 (0.33) | — | |
| SCHEMBL6997971 | 0.79 | HTR7 (0.36) | TDP1KMT2A | |
| SCHEMBL6999266 | 0.78 | DRD2 (0.47) | — | |
| SCHEMBL6998668 | 0.78 | HTR1A (0.53) | — | |
| SCHEMBL6994589 | 0.78 | HDAC2 (0.35) | KMT2A | |
| SCHEMBL6994591 | 0.78 | DRD2 (0.51) | — | |
| SCHEMBL6998180 | 0.78 | HTR7 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | LMNA 376/4885SMN1; SMN2 1611/4885TDP1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.